http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EA-022878-B1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_18258b0f0aeb7478e1258cb440bb4b83 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D493-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D493-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-34 |
| filingDate | 2008-12-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_92cdec641db66c78febe005143e4577e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_25865e267c6c9145672ae4167ec30253 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a82cae0f853e2b2afc49253c45dc742f |
| publicationDate | 2016-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EA-022878-B1 |
| titleOfInvention | EFFICIENT PROCARAMENTS ASPIRIN |
| abstract | Aspirin is one of the most widely used drugs for treating inflammation, pain, and fever. It has later found applications for preventing heart attacks and stroke and is being investigated as a chemopreventive agent against cancer. Despite its importance, aspirin is still underused because it causes gastric bleeding. The technology being developed potentially eliminates this problem. It is designed to reduce the contact between the drug and the inner intestinal walls. Thus, the prodrug compound isosorbide aspirinate is contemplated. The compound has the general structure as shown by the formula (I) where OR is -OC (O) C-C1-6 alkyl group, -OC (O) C-Alkoxy group, -OC (O) C-Cycloalkyl group or -OC (O) C - Cycloalkoxy group; which may be unsubstituted or substituted by ONO; or where R is benzoate, nicotinate, isonicotinate, oxazoloate, isoxazoloate or thiadiazoloate, which may be substituted by at least one group consisting of hydroxide, -Cl, -Br, C-C1-6 alkyl, C-Salkoxy, benzyloxy, -NHC ( O) R ', -NH, -NO, - (CH) ONO, -OCOAr, where R' is a C 1 -C 6 alkyl group, n = 1-8, and Ar is a phenyl; and its pharmaceutically acceptable salt and / or its hydrates. |
| priorityDate | 2007-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 239.